CCL21 and systemic sclerosis: Before MS analysis of the CCL21 IP product from SSc serum samples, we tested one antibody binding to an aa-sequence present in both full length CCL21 and tailless CCL21, and an antibody binding only to the C-terminal of CCL21 in IP analysis of full length CCL21.